Wellmarker Bio
The purpose of the present study is to determine the safety, tolerability, and efficacy of WM-A1-3389 in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancer (NSCLC).
Advanced Solid Tumor
Metastatic Solid Tumor
Lung Cancer
Colorectal Cancer
Pancreatic Cancer
Cholangiocarcinoma
Head and Neck Cancer
Non Small Cell Lung Cancer
WM-A1-3389
Pembrolizumab
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 54 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | An Open-label, Dose-escalation, Phase 1 Study to Investigate the Safety and Tolerability of WM-A1-3389, in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer |
Actual Study Start Date : | March 14, 2024 |
Estimated Primary Completion Date : | February 22, 2026 |
Estimated Study Completion Date : | February 22, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Dose escalation (Stage 1) WM-A1-3389 administered intravenously, weekly for 21 days of each cycle |
Biological: WM-A1-3389 |
Experimental: Dose escalation (Stage 2) WM-A1-3389 administered intravenously, weekly for 21 days of each cycle Pembrolizumab 200 mg administered intravenously, every 3 weeks for 21 days of each cycle |
Biological: WM-A1-3389 |
Ages Eligible for Study: | 19 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Seoul St. Mary's Hospital
Seoul, Seo Chogu, Korea, Republic of, 06591
Recruiting
Incheon St. Mary's Hospital
Incheon, Ye sound sooooooooooooo much Korea, Republic of, 21999